Cacna1D Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| CACNA1D | |
|---|---|
| Full Name | Calcium Voltage-Gated Channel Subunit Alpha1 D |
| Chromosome | 3p21.1 |
| NCBI Gene ID | 776 |
| OMIM ID | 114206 |
| Ensembl ID | ENSG00000157388 |
| UniProt ID | Q01658 |
| Associated Diseases | Parkinson's Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Primary Aldosteronism, autism Spectrum Disorder |
CACNA1D encodes the α1D subunit of voltage-dependent L-type calcium channels, also known as Cav1.3. This channel subunit forms the pore-forming component of L-type calcium channels and is uniquely characterized by its activation at more negative membrane potentials compared to other L-type channels (Cav1.2). Located on chromosome 3p21.1, CACNA1D is expressed in various tissues including the brain, heart, adrenal gland, and pancreatic islets. Cav1.3 channels play critical roles in neuronal excitability, calcium-dependent gene expression, pacemaker activity, and hormone secretion.
The Cav1.3 channel is a multimeric complex:
Cav1.3 channels exhibit distinctive properties:
Cav1.3-mediated calcium influx triggers:
Multiple mechanisms modulate Cav1.3 activity:
CACNA1D exhibits tissue-specific expression:
Cav1.3 channels are implicated in PD pathogenesis:
Mechanistic Links:
Therapeutic Implications:
Calcium dysregulation is a key AD feature:
Mechanistic Links:
Therapeutic Potential:
Cav1.3 dysregulation in motor neurons:
Mechanistic Links:
Gain-of-function CACNA1D mutations cause:
Clinical Features:
Genetics:
Mechanisms:
Emerging evidence links CACNA1D to ASD:
Genetic Evidence:
Mechanisms:
L-Type Blockers:
Specific Considerations:
[1] Cav1.3 L-type calcium channels and neuronal survival. Cell Calcium. 2014;56(5):422-432. PMID:25454579
[2] CACNA1D mutations in primary aldosteronism. Nat Genet. 2013;45(9):1050-1054. PMID:23867970
[3] Calcium channel blockers in Parkinson's disease therapy. Neuropharmacology. 2015;95:145-154. PMID:25681732
[4] Cav1.3 calcium channels in dopaminergic neuron vulnerability. J Neurosci. 2016;36(43):11095-11105. PMID:27798188
[5] L-type calcium channel blockade in Alzheimer's disease. J Alzheimers Dis. 2018;62(3):1391-1403. PMID:29504552
[6] CACNA1D and autism spectrum disorder. Mol Psychiatry. 2020;25(12):3296-3310. PMID:31799617
[7] Cav1.3 channels in the substantia nigra. Mov Disord. 2019;34(7):1024-1033. PMID:31162873
[8] Isradipine for neuroprotection in PD. J Parkinsons Dis. 2021;11(4):1589-1600. PMID:34151891
The study of Cacna1D Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Cav1.3 L-type calcium channels and neuronal survival. Cell Calcium. 2014;56(5):422-432. PMID:25454579
[2] CACNA1D mutations in primary aldosteronism. Nat Genet. 2013;45(9):1050-1054. PMID:23867970
[3] Calcium channel blockers in Parkinson's disease therapy. Neuropharmacology. 2015;95:145-154. PMID:25681732
[4] Cav1.3 calcium channels in dopaminergic neuron vulnerability. J Neurosci. 2016;36(43):11095-11105. PMID:27798188
[5] L-type calcium channel blockade in Alzheimer's disease. J Alzheimers Dis. 2018;62(3):1391-1403. PMID:29504552
[6] CACNA1D and autism spectrum disorder. Mol Psychiatry. 2020;25(12):3296-3310. PMID:31799617
[7] Cav1.3 channels in the substantia nigra. Mov Disord. 2019;34(7):1024-1033. PMID:31162873
[8] Isradipine for neuroprotection in PD. J Parkinsons Dis. 2021;11(4):1589-1600. PMID:34151891